Long-term efficacy and safety of damoctocog alfa pegol prophylaxis in patients with haemophilia A aged 12- & lt;18 years at enrolment into PROTECT VIII

Conclusion Efficacy and safety of damoctocog alfa pegol was confirmed in adolescent patients with haemophilia A, with data for up to 6 years supporting its use as a long-term treatment option in this group as they transition into adulthood.PMID:38599195 | DOI:10.1159/000538702

Source: Acta Haematologica - April 10, 2024 Category: Hematology Authors: Mark T Reding Mindy Simpson Jonathan Ducore P ål Andrè Holme Monika Maas Enriquez Maria Elisa Mancuso Source Type: research